Efficacy and safety of damoctocog alfa pegol prophylaxis in patients â©¾40 years with severe haemophilia A and comorbidities: <i>post hoc</i> analysis from the PROTECT VIII study.

Reding, Mark T; Pabinger, Ingrid; Holme, Pål Andrè; Maas Enriquez, Monika; Mancuso, Maria Elisa; Lalezari, Shadan; Miesbach, Wolfgang; Di Minno, Giovanni; Klamroth, Robert; Hermans, Cedric

Efficacy and safety of damoctocog alfa pegol prophylaxis in patients â©¾40 years with severe haemophilia A and comorbidities: post hoc analysis from the PROTECT VIII study.

Reding, Mark T; Pabinger, Ingrid; Holme, Pål Andrè; Maas Enriquez, Monika; Mancuso, Maria Elisa; Lalezari, Shadan; Miesbach, Wolfgang; Di Minno, Giovanni; Klamroth, Robert; Hermans, Cedric.

Afiliação

Reding MT; Center for Bleeding and Clotting Disorders, University of Minnesota Medical Center, 420 Delaware Street SE, MMC 480, Minneapolis, MN 55455, USA.
Pabinger I; University Clinic for Internal Medicine I, Medical University of Vienna, Vienna, Austria.
Holme PA; Department of Haematology, Oslo University Hospital and Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
Maas Enriquez M; Bayer AG, Wuppertal, Germany.
Mancuso ME; Center for Thrombosis and Hemorrhagic Diseases, IRCCS Humanitas Research Hospital, Milan, Italy; Humanitas University, Milan, Italy.
Lalezari S; National Haemophilia Centre, Chaim Sheba Medical Centre, Tel Aviv University, Tel Aviv, Israel.
Miesbach W; University Hospital Frankfurt, Frankfurt am Main, Germany.
Di Minno G; Department of Clinical and Experimental Medicine, University of Naples Federico II, Naples, Italy.
Klamroth R; Vivantes Hospital Friedrichshain, Berlin, Germany.
Hermans C; Division of Haematology, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain (UCLouvain), Louvain, Belgium.